Page last updated: 2024-11-12

santalol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

santalol: combination of alpha and beta isomers [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12315259
SCHEMBL ID10980513
MeSH IDM0127277

Synonyms (12)

Synonym
11031-45-1
santalol
2-penten-1-ol, 2-methyl-5-[(1s,2r,4r)-2-methyl-3-methylenebicyclo[2.2.1]hept-2-yl]-, (2z)-
2-methyl-5-((1s,2s,4r)-2-methyl-3-methylenebicyclo[2.2.1]heptan-2-yl)pent-2-en-1-ol
SCHEMBL10980513
(e)-2-methyl-5-[(1s,2s,4r)-2-methyl-3-methylidene-2-bicyclo[2.2.1]heptanyl]pent-2-en-1-ol
A894911
73890-74-1
(E)-2-METHYL-5-((1S,2S,4R)-2-METHYL-3-METHYLENEBICYCLO[2.2.1]HEPTAN-2-YL)PENT-2-EN-1-OL
(2e)-2-methyl-5-[(1s,2s,4r)-2-methyl-3-methylidenebicyclo[2.2.1]heptan-2-yl]pent-2-en-1-ol
DTXSID601121647
rel-(2e)-2-methyl-5-[(1r,2r,4s)-2-methyl-3-methylenebicyclo[2.2.1]hept-2-yl]-2-penten-1-ol

Research Excerpts

Overview

Santalol is a bioprospecting molecule present in sandalwood. Any effort towards metabolic engineering of this important moiety would require knowledge on gene regulation.

ExcerptReferenceRelevance
"Santalol is a bioprospecting molecule present in sandalwood and any effort towards metabolic engineering of this important moiety would require knowledge on gene regulation."( Molecular regulation of santalol biosynthesis in Santalum album L.
Kush, A; Rani, A; Ravikumar, P; Reddy, MD, 2013
)
1.42

Treatment

α-Santalol pretreatment strongly inhibited UVB-induced epidermal hyperplasia and thickness of the epidermis. It also inhibited expression of proliferation and inflammation markers proliferating cell nuclear antigen (PCNA), Ki-67 and cyclooxygenase 2 (Cox-2)

ExcerptReferenceRelevance
"α-Santalol pretreatment strongly inhibited UVB-induced epidermal hyperplasia and thickness of the epidermis, expression of proliferation and inflammation markers proliferating cell nuclear antigen (PCNA), Ki-67 and cyclooxygenase 2 (Cox-2)."( α-Santalol, a skin cancer chemopreventive agent with potential to target various pathways involved in photocarcinogenesis.
Dwivedi, C; Santha, S,
)
1.41
"α-santalol treatment inhibited ex vivo and in vivo angiogenesis as evident by rat aortic and sponge implant angiogenesis assay."( α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway.
Alhaider, AA; Kumar, S; Saraswati, S, 2013
)
1.67
"α-Santalol treatment also resulted in activation of caspase-3 activity and PARP cleavage."( α-Santalol, a derivative of sandalwood oil, induces apoptosis in human prostate cancer cells by causing caspase-3 activation.
Bommareddy, A; Dwivedi, C; Rule, B; Santha, S; VanWert, AL, 2012
)
1.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (62)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (4.84)18.7374
1990's1 (1.61)18.2507
2000's14 (22.58)29.6817
2010's37 (59.68)24.3611
2020's7 (11.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.28 (24.57)
Research Supply Index4.23 (2.92)
Research Growth Index5.24 (4.65)
Search Engine Demand Index65.74 (26.88)
Search Engine Supply Index2.04 (0.95)

This Compound (44.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.49%)5.53%
Reviews5 (7.46%)6.00%
Case Studies1 (1.49%)4.05%
Observational0 (0.00%)0.25%
Other60 (89.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]